Physician profile
Shelly Agarwal
NPI 1225284078
$31,963.21
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2021: $171 · 2022: $8,227 · 2023: $10K · 2024: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $22K · Food and Beverage: $857 · Travel and Lodging: $85.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $22,242.17 |
| Food and Beverage | $857.02 |
| Travel and Lodging | $85.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $30,204.53 | 2022-2024 | Nexplanon |
| Hologic Sales and Service, LLC | $779.30 | 2019-2024 | Novasure, Acessa Provu System, Coolseal Generator |
| Abbvie INC. | $385.39 | 2019-2023 | Lo Loestrin Fe |
| Myriad Women'S Health, INC. | $195.19 | 2023 | Myrisk |
| Aspira Women'S Health INC | $156.89 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $64.34 | 2022-2023 | |
| Coopersurgical, INC. | $45.81 | 2021-2023 | Paragard T 380a |
| Novo Nordisk INC | $24.18 | 2023 | Wegovy |
| Agile Therapeutics, INC. | $22.74 | 2022 | |
| Astellas Pharma US INC | $20.42 | 2023 | Veozah |
| Roche Diagnostics Corporation | $19.66 | 2019 | |
| Merck Sharp & Dohme LLC | $15.49 | 2019 | |
| Acessa Health INC. | $15.27 | 2019 | |
| Minerva Surgical, INC | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelly Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.